Polyrizon Ltd., a biotech company based in Raanana, Israel, announced a successful preliminary safety study for its PL-14 Allergy Blocker, an innovative intranasal hydrogel designed to provide a ...

--Polyrizon Ltd., a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that on April 8, 2025, the Company received a written ...

Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap ...

Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap ...

With this agreement, Polyrizon secures a reliable and compliant manufacturing source for the PL-14 clinical trial. The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker ...

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial Dec. 02, 2024 8:02 AM ET Polyrizon Ltd. (PLRZ) ...

Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device ...

Polyrizon Ltd. set terms for its initial public offering on Friday, with plans to offer 3.1 million units priced at $5.20 to $7.20 a pop. Each unit will consist of one ordinary share and three ...

RAANANA, ISRAEL - Polyrizon Ltd. (NASDAQ: PLRZ), a biotech company known for its hydrogel technology, has successfully completed a private placement, securing approximately $17 million through the ...

What Happened: The after-hours price of Polyrizon’s stock was $0.92, marking a 12.02% dip from the previous day’s closing price of $1.04. This follows a regular trading session surge of 52.47%.

Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap ...